Lead Product(s) : NKTR-255,C-TIL051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cellular Biomedicine Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will evaluate Nektar's NKTR-255, a novel IL-15 receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory...
Product Name : NKTR-255
Product Type : Protein
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : NKTR-255,C-TIL051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cellular Biomedicine Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NKTR-255
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response.
Product Name : NKTR-255
Product Type : Protein
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : NKTR-255
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NKTR-255,Daratumumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response.
Product Name : NKTR-255
Product Type : Protein
Upfront Cash : Inapplicable
August 16, 2022
Lead Product(s) : NKTR-255,Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NKTR-255,Obinutuzumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cairo Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NKTR-255, an investigational IL-15 receptor agonist, enhances expression of NK cell-activating receptors, stimulates NK cell proliferation and sustains NK cell expansion, it also enhances anti-MCAM CAR NK cell cytotoxicity against sarcoma's and neuroblas...
Product Name : NKTR-255
Product Type : Protein
Upfront Cash : Inapplicable
April 23, 2022
Lead Product(s) : NKTR-255,Obinutuzumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cairo Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the Phase 2 study of bempegaldesleukin/Opdivo doublet in patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer, a final ORR analysis assessed by BICR showed that bempegaldesleukin in combination with Opdivo did not reach...
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Inapplicable
April 14, 2022
Lead Product(s) : Bempegaldesleukin,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : SFJ Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
Details : The collaboration between SFJ and Nektar will support a new Phase 2/3 registrational clinical study of BEMPEG plus pembrolizumab in patients with head and neck cancer whose tumors express PD-L1 (Combined Positive Score).
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Bempegaldesleukin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : SFJ Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
Lead Product(s) : Bempegaldesleukin,VB10.NEO
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Nykode Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine.
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Bempegaldesleukin,VB10.NEO
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Nykode Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempegaldesleukin,Axitinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials.
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Undisclosed
October 01, 2020
Lead Product(s) : Bempegaldesleukin,Axitinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Nektar Therapeutics To Present at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Details : The presentations includes clinical data for three Nektar-sponsored studies, including updated clinical data from a cohort of first-line Stage IV metastatic melanoma patients in the PIVOT-02 study of bempegaldesleukin with nivolumab and Nektar's NKTR-255...
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Inapplicable
September 11, 2020
Details : Data show that BEMPEG, in combination with nivolumab, increases T-cell infiltration into the tumor microenvironment and increases PD-L1 expression on-treatment, leading to very encouraging response rates.
Product Name : Bempeg
Product Type : Protein
Upfront Cash : Inapplicable
May 22, 2020